中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

股票代码/Stock Code：1177 HK

2022年全年业绩发布会

2022 Annual Results Announcement

2023.3.31 Hong Kong

Agenda

- **Financial highlights**
- Four key therapeutic areas
- BD & Globalization
- Efficiency improvement
- Future outlook
- Appendix

Key financials: revenue and underlying profits consistently grew

(RMB bn)

Revenue



Adjusted non-HKFRS attributable earnings[1)]



Gross profit



Attributable earnings



Note: 1) Adjusted non-HKFRS attributable earnings is presented as an additional financial measure to provide supplementary information for better assessment of the performance of Sino Biopharm's core operations. Sino Biopharm is committed to maintaining the stability of this adjustment basis for investors' reference. Please refer to the next page for details.

Adjusted non-HKFRS attributable earnings

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

(RMB bn)	2022	2021	Change%
Profit attributable to the owners of the parent	2.54	14.61	-82.6%
Share of losses/(profits) of associates and a joint venture (net of related tax and non-controlling interests)[1)]	0.12	-12.44	
One-off adjustments for the impairment and fair value changes of certain assets and liabilities (net of related tax and non-controlling interests)	0.22	0.86	
Fair value losses of current equity investments, net	0.20	0.01	
Share-based payments	0.03	-	
Loss on extinguishment of partial convertible bond	0.01	-	
Fair value gain of convertible bond embedded derivative component	-0.07	-0.24	
Convertible bond debt component of:			
Effective interest expenses	0.08	0.11	
Exchange gain	-0.25	-0.35	
Fair value losses of derivative financial instruments in relation to foreign currency forward contracts	0.11	-	
Adjusted non-HKFRS attributable earnings	**2.99**	**2.56**	**+16.4%**

Note: 1) Large difference vs. 2021 mainly due to share of profit from an associate dropped vs. previous year

Therapeutic area results

(RMB bn)

Revenue by TA



Four key TAs

	2022 revenue	GR%
Oncology	9.19	14.3%
Surgery/ analgesic	4.88	2.8%
Liver disease	3.84	15.4%
Respiratory	2.92	-6.5%
Cardio-cerebral	2.70	7.8%
Others	5.25	2.5%

Highlights:

Oncology

- Focus V (Anlotinib Hydrochloride capsules) was approved for the 5th indication, differentiated thyroid carcinoma, in 2022 H1.
- Annike (Penpulimab monoclonal antibody injection) was approved for the treatment of 3rd line cHL in 2021 and the treatment of 1st line sNSCLC in 2023. In addition, it has one indication (3rd line NPC) under marketing review.

Surgery/analgesic

- Debaian (Flurbiprofen cataplasms) made significant progress in expansion into lower-tier cities and multi-TA.
- Kelitone (Limaprost tablet) was approved by NMPA in 2023. It is the first and only drug in China to address the pathological mechanism of lumbar spinal stenosis.

Liver disease

- Tianqing ganmei (Magnesium Isoglycyrrhizinate injection) achieved substantial revenue growth through strong promotional strategies.

Respiratory

- Tianqingsuchang (Budesonide Suspension for Inhalation), first generic of its kind launched in China, won the bid in the fifth batch of centralized procurement.
- Tianyun (Colistimethate Sodium for injection) was included in the National Reimbursement Drug List in 2022, becoming the polymyxin drug with the lowest daily treatment cost in China. It is expected to achive high sales growth in 2023.

Innovation: number of innovative drugs starts to surge

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED



R&D: expenditure further increased with focus on innovation



Note: Total R&D expenditure includes expensed (2022: 95.5%) and capitalized amounts

SG&A: remarkable progress achieved in operating efficiency improvement

(RMB bn)

47.3%
SG&A ratio 2021

43.7%
SG&A ratio 2022



Number of sales staffs[1)]



Output per sales staff - major subsidiaries[2)]



Note: 1) Number of sales staffs is the total number of sales staffs under Sino Biopharm (including its subsidiaries) at the end of the reporting period; 2) Output per sales staff – major subsidiaries = Revenue of 6 major subsidiaries / Average number of sales staffs in 6 major subsidiaries, major subsidiaries include: CTTQ, Beijing Tide, Nanjing CTTQ, CP Pharm (Qingdao), CTFH, CTQJ

Production: efficiency improvement led to stable gross profit margin under price pressure

(RMB bn)

80% Gross profit margin 2018 → **80%** Gross profit margin 2021 → **80%** Gross profit margin 2022



Output batches per production staff - major subsidiaries[1)]



Note: 1) Output batches per production staff - major subsidiaries = Number of output batches of 6 major subsidiaries / Average number of production staffs in 6 major subsidiaries (excl. management level), major subsidiaries include: CTTQ, Beijing Tide, Nanjing CTTQ, CP Pharm (Qingdao), CTFH, CTQJ

Agenda

- Financial highlights
- **Four key therapeutic areas**
- BD & Globalization
- Efficiency improvement
- Future outlook
- Appendix

Address unmet healthcare needs, lead the future development of 4 TAs

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Science for a healthier world

Oncology
Top 3[1)]

4mn new cases per year

Liver disease
Top 1[1)]

0.1bn HBV and NASH patients

Surgery/analgesic
Top 1[1)]

0.1bn surgical patients

Respiratory
Top 1[1)]

0.2bn patients with interstitial, obstructive and infectious lung diseases

Cumulative number of patients treated

Anlotinib Hydrochloride Capsules	0.7mn
Abiraterone Acetate Tablets	0.1mn
Magnesium Isoglycyrrhizinate Injection	30mn
Entecavir Dispersible Tablets	3.5mn
Flurbiprofen Cataplasms	75mn
Calcitriol Soft Capsules	40mn
Budesonide Suspension for Inhalation	8.9mn

Note: 1) 2030 target (market share in China)

Oncology: competitive portfolio with RMB10bn+ peak sales, blockbuster Anlotinib as the core

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

2018-2022 revenue CAGR: 39%

- Approved for the 5th indication, differentiated thyroid carcinoma (DTC), in 2022 H1
- 5 indications: 3rd line NSCLC, 3rd line SCLC, STS, MTC and DTC
- Patents valid until **2032**

2021-2022 revenue CAGR: 119%

- Approved in 2021 for 3rd line cHL
- Approved in 2023 for 1st line sNSCLC
- 3rd line NPC: NDA submitted in China

TQB2450
Anti PD-L1

NDA submitted in China

- The Phase III clinical trial of Anlotinib in combination with TQB2450 (Anti-PD-L1) for the treatment of 1st line SCLC has completed interim analysis and met the pre-specified endpoint. The data will be announced at the WCLC in Sep.
- NDA submitted to CDE in Jan 2023.

Combination therapy

Mono	NSCLC (3rd line)	Approved
	SCLC (3rd line)	Approved
	STS	Approved
	MTC	Approved
	DTC	Approved
Chemo	RAS-BRAF wild-type CRC (1st line)	Phase III
	STS (1st line)	Phase III
	Ovarian cancer (2nd line)	Phase III
PD-1	HCC (1st line)	Phase III
	HCC (adjuvant)	Phase III
PD-L1	SCLC (1st line)	NDA
	NSCLC (1st line)	Phase III
	nsNSCLC (1st line)	Phase III
	sNSCLC (1st line)	Phase III
	RCC (1st line)	Phase III
	Endometrial cancer	Phase III

Peak sales: RMB 10bn+

Oncology:
Ryzneuta, potential blockbuster to be approved soon

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Background: Evive Biotech licensed China rights of its novel G-CSF Ryzneuta™ (F-627) to Sino Biopharm

Highlights

- **3rd generation rhG-CSF**: novel long-acting G-CSF, PEG-related potential issues avoided
- Better efficacy vs. 2nd generation; well positioned for patients not responding consistently or allergic to current therapies
- Solid clinical data: **the only** G-CSF on market with large sample head-to-head comparative study results against both long and short-acting competitors
- Good clinical progress: phase III completed and BLA filed in both China and US; currently no competitor of 3rd generation in China
- May 2021: BLA accepted by FDA; approval expected by 2023
- February 2022: BLA accepted by NMPA; **approval expected by 2023**
- Unique success factors of Sino Biopharm: top-tier oncology commercialization team, good collaboration with physicians nationwide, and strong brand awareness

Substantial unmet clinical needs[1)2)]



ROFR for F-652

- Sino Biopharm also obtained ROFR for Evive first-in-class biologic product F-652 (rh IL-22 dimer) in indications of AHH and ACLF in China
  - AHH: IIa study completed
  - ACLF: preclinical study competed, IND for phase II filed

Note: 1) Source: MENET 2020 data; 2) Assuming short-acting G-CSF market with -3% annual growth rate vs. 15% for long-acting G-CSF market

Liver disease: all-round NASH pipeline layout in late clinical-stage

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Global R&D	Target[1)]	Main mechanism of action	Type	POC	Efficacy	Safety	Sino Biopharm
Phase III	FXR	bile acid	Oral/Small molecule	✓	★★☆	★☆☆	✓
	PPAR	glucose metabolism, lipid metabolism, inflammation, fibrosis	Oral/Small molecule	✓	★★★	★★★	✓
	GLP-1	glucose metabolism, inflammation	Injection/ Macromolecule	✓	★★★	★★☆	✓
	THR-β	lipid metabolism, inflammation	Oral/Small molecule	✓	★★☆	★★★	✓
	SCD-1	lipid metabolism, inflammation	Oral/Small molecule	-	★☆☆	★★★	
Phase II	FGF-21	glucose metabolism, lipid metabolism, inflammation	Injection/ Macromolecule	✓	★★★	★★★	✓
	KLB	glucose metabolism, lipid metabolism, inflammation	Injection/ Macromolecule	-	Not yet released	Not yet released	✓
	GIP/GLP-1	glucose metabolism, lipid metabolism, inflammation	Injection/ Macromolecule	-	Not yet released	Not yet released	
	Caspase	inflammation	Oral/Small molecule	-	Not yet released	Not yet released	✓
Phase I	FGF-21/GLP-1	glucose metabolism, lipid metabolism, inflammation	Injection/ Macromolecule	-	Not yet released	Not yet released	✓

✓ Internal R&D ✓ External BD

Note: 1) Drug targets FXR, PPAR, or GLP-1 have relatively better efficacy, and have obtained FDA Breakthrough Therapy designation; 2) Source: clinicaltrial.gov, official websites of multiple companies

Liver disease:
Lanifibranor, potential BIC oral drug for NASH globally, FIC in China

Current stage:
Phase III in US and China

The first oral drug for NASH that has entered Phase III clinical trial in China.



Note: Source: Inventiva

Surgery/analgesic:
Limaprost, the first & only drug in China to address lumbar spinal stenosis

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

~32mn middle-aged and elderly population

Kelitone® (Limaprost)

Synthetic derivative of prostaglandin E1

Pharmacological effects:

- Improving peripheral circulation disorders
- Increasing blood flow to nerve tissues
- Improving hyperalgesia
- Improving nerve function

01	02	03	04	05
Unmet needs	**First and Only**	**Breakthrough production tech**	**Good efficacy**	**Convenience**
• Spinal stenosis: common disease in the middle-aged and elderly population, annual diagnosis of **30mn+** patients in China • Conservative treatments have limited efficacy, and elderly patients may have many contraindications to surgery	• The **only** small-molecule drug with a specific indication for the treatment of lumbar spinal stenosis • **First** in China	• The **world's first** human biological samples detection and analysis method with a minimum quantitative concentration of pg level • **Uniform** and **stable** content level even at 0.006% ultra-low tablet weight ratio • Overcoming the difficulty of instability of prostaglandins to prepare **oral** drugs	• Dual effect of **improving neurological microcirculation** and **neurological function** • Relief the three major symptoms of lumbar spinal stenosis, including **intermittent claudication**, **pain**, and **numbness**	• Special structure, difficult to be metabolized by enzymes in the digestive system • **Oral** drug, more convenient

Surgery/analgesic: PL-5, address the unmet market needs for "drug-resistant bacteria" anti-infective drugs

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Completed Phase III clinical study for the treatment of secondary wound infections

Innovation

The **first antimicrobial peptide** in China

The **first non-antibiotic antimicrobial**

Broad-spectrum

G+, G- bacteria, and **drug-resistant bacteria**

Low drug resistance

Low risk of drug resistance and no cross-resistance

Safety

Topical application, **no blood penetration**, better safety

Good competitive environment

No competitors and no VBP risk in the short term

Topical medication, generics need to go through clinical trials

Convenience

Spray is easy to use, and can evenly spray the wound surface

Large unmet market

~30mn patients with burn wound infection, diabetic foot wound infection, traumatic wound infection, etc.

Respiratory:
Ensitrelvir, potential best-in-class COVID-19 oral drug

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Broader scope of patients

Ensitrelvir

- Japan: applicable to **all COVID-19 patients**, ≥12 years old
- Clinical trials: not limited to high risk patients, most Asian, > 80% vaccinated[1)]

Paxlovid

- China: high risk of disease progression, adults

Safe and convenient

Ensitrelvir

- **Single drug**, once a day
- No serious treatment related TEAE[4)] were observed in the clinical trials

Paxlovid

- Must be co-administered with Ritonavir, records of hepatotoxicity

Key features

Better efficacy

Ensitrelvir

- Symptom resolution: **significant alleviation and reduction in the time to resolution of 5 key COVID-19 symptoms**[2)]
- Antiviral: the proportion of patients with **positive virus titers** in the drug groups **decreased significantly**, reaching significant differences[3)]
- Clinical trials: **Omicron** patients

Paxlovid

- Clinical trials: Delta patients

Market recognition

Ensitrelvir

- **Approved** under the emergency regulatory approval system in Japan
- Japan and U.S. governments have each ordered 2 million doses

Note: 1) Phase II and phase III; 2) 5 key COVID-19 symptoms: stuffy or runny nose, sore throat, cough, feeling hot or feverish, low energy or tiredness; 3) Compared with the placebo group, the proportion of patients with positive virus titers in the low-dose group and high-dose group decreased by 98.1% and 94.6% respectively on day 4 in phase IIb; 4) TEAE: Treatment-emergent adverse events

Agenda

- Financial highlights
- Four key therapeutic areas
- **BD & Globalization**
- Efficiency improvement
- Future outlook
- Appendix

BD: advance existing pipelines and platforms, accelerate growth in key TAs

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

	Innovative pipelines	Innovative platforms
Oncology	Akesobio: **BIC PD-1** Immuno-oncology Servier: **LAG3** Immuno-oncology	F-star THERAPEUTICS: World-leading **Bispecific Abs Platform**
	EVIVE BIOTECH: **BIC G-CSF** Millions of CIN patients	pHion THERAPEUTICS: World-leading **mRNA Delivery Platform**
Liver disease	AMPSOURCE: **FIC FGF21** **BIC FGF21/GLP-1** inventiva: **FIC pan-PPAR** 50mn NASH patients	
Respiratory	SHIONOGI: **BIC 3CL** COVID-19	SOFT HALE: One of the only 2 **Soft Mist Inhalation Platforms** in the world
Surgery/ analgesic	普莱医药 ProteLight Pharma: **FIC Antimicrobial peptide** 30mn patients with wound infection	

invoX: acquire F-star to accelerate bsAb development globally

F·star THERAPEUTICS

A clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy

66 Scientific staffs

500+ Patents

5 Global MNC partnerships

Transaction overview:

- Consideration: ~US$161mn (or $7.12 per share)
- Regulatory approvals:

  UK: National Security and Investment Act (NSIA)

  US: Committee on Foreign Investment in the United States (CFIUS)

First China pharma deal to obtain CFIUS approval in the last 3 years, making invoX and Sino Biopharm a preferred partner for international collaborations with all MNCs and biotech/biopharma companies



Differentiated MoA

- **Crosslinking:** better avidity
- **Clustering:** drive potent immune cell activation
- **Conditionality:** strong localized antitumor effect

Unique Bispecific Structure

- **Natural human IgG antibody format** with only 15-20 amino acid substitutions
- **Reduced** potential for **immunogenicity**
- **Simplified manufacturing**

Program	Target (MoA)	Opportunity	Preclinical	Phase I	Phase II
FS118	**LAG-3 / PD-L1** (Dual Inhibitor)	Rescuing CPI treatment failures		Head & Neck cancer	
		Improving outcomes in CPI naïve		NSCLC & DLBCL	
FS222	**CD137 / PD-L1** (Stimulator/Inhibitor)	Improving outcomes in PD-L1 low tumors			
FS120	**OX40 / CD137** (Dual Stimulator)	Improving CPI and chemotherapy outcomes			

F-star: key milestones in clinical development

	2023	2024	2025	2026	2027	Expanding
FS118 LAG-3/ PD-L1	• NSCLC (CPI-naiive): interim readout, final readout • DLBCL (CPI-naiive): interim readout, final readout • H&N (AR): interim readout, final readout	• H&N (AR): initiation of Paclitaxel combo Phase II/III			• BLA	
FS222 CD137 /PD-L1	• Interim readout from dose escalation • Complete dose escalation and explore efficacy in targeted tumor types	• Interim readout in at least two indication specific cohorts	• Breakthrough therapy designation		• BLA	
FS120 OX40/ CD137	• Safety and pharmacology data from mono and pembrolizumab combination	• Interim readout from at least three indication specific pembrolizumab combination cohorts	• Breakthrough /fast track pivotal trial starts		• BLA	
	• Integration • R&D Day					

Modality

Multi-specifics

Bispecific-ADC

TA

CNS

Autoimmune

F-star: improve reputation/collaboration with multiple global partners

Immuno-oncology Program — **Development of 2 bsAbs**

Takeda

Grant Takeda a worldwide, exclusive licence to research, develop, and commercialize **2 bispecific antibodies** directed towards immuno-oncology targets using F-star's proprietary **Fcab** and **mAb²** platforms.

July 2022

- Upfront: US$1mn
- Developmental and commercial milestones: up to US$40mn
- Royalties: single digit percentage

March 2023

- Upfront, milestones, royalties

Next Generation bsAb — **Development of up to 5 bsAbs**

Janssen Pharmaceutical Companies of Johnson & Johnson

Oct 2021

- Milestones: Up to US$1.35bn
- Royalties

STING inhibitors — **Exclusive rights to novel preclinical STING inhibitors**

AstraZeneca

July 2021

- Milestones: up to US$63mn
- Royalties

Immuno-oncology Program — **Development of up to 3 bsAbs**

Merck KGaA, Darmstadt

July 2020 / May 2019

- Milestones: up to US$766mn
- Royalties

Upfront payments and milestones to date: **US$251mn**

Future milestones: up to **US$2.2bn**

Agenda

- Financial highlights
- Four key therapeutic areas
- BD & Globalization
- **Efficiency improvement**
- Future outlook
- Appendix

CTTQ:
Commercialization: from ‘mixed’ to ‘specialized’



Output per sales staff – CTTQ[1)]



Note: 1) Output per sales staff – CTTQ = Revenue of CTTQ / Average number of sales staffs in CTTQ

CTTQ:
R&D: from ‘generics + innovation’ to fully innovation driven

正大天晴 CHIATAI TIANQING

2019

R&D

Biological drugs	Chemical drugs	Clinical development	Shared functions
Discovery	Innovation	Clinical operation	Pharmacology
CMC	Nanjing	Clinical support	Registration
	Lianyungang		Quality

2022

R&D

Innovative biological drugs	Innovative chemical drugs		Generics	Clinical dev.	Shared functions
Discovery	Discovery	Innovation	Pilot-scale	Operation (discovery)	Pharma-cology
CMC	CMC	CMC	CMC	Operation (registration)	Registration
				Support	Quality

Shanghai Innovative R&D Center

Shanghai Innovative R&D Center

R&D Lab

1、Innovative antibody design and primary screening lab
2、Cell and gene lab
3、Innovative technology lab
4、Microgravity simulation condition lab for biological drugs

Innovative Platform

1、AI aided drug development
2、ADC development platform
3、Universal CAR-T cell therapy development platform
4、Viral gene therapy development platform
5、Other cutting-edge fields

CTTQ:
Production: from ‘stand-alone’ to ‘pool sharing’

2019

Group production system
Lianyungang Runzhong Pharma
Nanjing Shunxin Pharma

2022

Production

- Haizhou production center
- Runzhong production center
- Shunxin production center
- **Shared functions**
  - Production supply
  - Quality control

Output batches per production staff – CTTQ[1)]



Note: 1) Output batches per production staff – CTTQ = Number of output batches of CTTQ / Average number of production staffs in CTTQ (excl. management level)

CTTQ:
Admin: from ‘traditional’ to ‘digitalized’

正大天晴 CHIATAI TIANQING

2019

Finance dept., Treasury dept., Accounting dept.
Finance & Accounting dept. (1/2/3/5)
Finance & Accounting dept. (Runzhong)

Organizational development dept.
Personnel affairs dept.
Runzhong HR dept.

2022

Finance

Finance COE	FABP	Accounting
Investment	Sales	COGS
Planning	R&D	General ledger
Tax	Production	Expenses
Operation	Admin	

HR

HR-COE	HRBP	HR-SSC
Organization dev.	Sales	Remuneration
Talent dev.	R&D	Recruitment
Project mgmt.	Production	Data
	Admin	

Incremental profits from digitization – CTTQ



CTTQ:
Procurement: centralized procurement to improve efficiency

CTTQ
Centralized Procurement 2022

Centralized procurement size	Centralized procurement %	Efficiency improvement
2.2bn	**57%**	**0.2bn**

- In 2022, CTTQ realized **RMB 0.2bn** in **efficiency improvement** through centralized procurement.
- In the process of developing a more **digitalized** and **systematic** procurement system.
- Developed an **in-house procurement platform 'Qingyoupin'** and would continue to promote group-wide usage in an orderly manner (2022 YE utilization rate: 65%).

Procurement size - CTTQ



Sino Biopharm:
Procurement: from company level to group level centralized procurement

Company level ‘centralized procurement’
From CTTQ to all subsidiaries

Procurement size – major subsidiaries[1)]



Group level ‘centralized procurement’
Unified supplier management across subsidiaries

RMB 10mn

2022Q4
Efficiency improvement



Note: 1) Major subsidiaries include: CTTQ, Beijing Tide, Nanjing CTTQ, CP Pharm (Qingdao), CTFH, CTQJ

Sino Biopharm:
Retail: integrate resources to accelerate retail business development

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Retail team – CTTQ

Retail team – Beijing Tide

Retail team - CTFH

Retail team – CP Pharm (Qingdao)

Group Retail Department

Eastern	Southern	Western
Northern	Central	NKA

Agenda

- Financial highlights
- Four key therapeutic areas
- BD & Globalization
- Efficiency improvement
- **Future outlook**
- Appendix

Outlook: innovative drugs to drive revenue growth

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Revenue from innovative drugs

(RMB, bn)



Revenue breakdown by innovative drugs vs. generics



Outlook: to be one of the top 30 big pharma companies globally with revenue exceeding HKD100bn by 2030.



中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

健康科技，温暖更多生命

Science for a healthier world

Agenda

- Financial highlights
- Four key therapeutic areas
- BD & Globalization
- Efficiency improvement
- Future outlook
- **Appendix**

Pipeline: Oncology
Innovative drugs: 46 products in clinical development

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

No.	Program	Target / MOA	Type	Indication	I	II	III	NDA/BLA
1	TQ-B3101	ALK/cMET TKI	Small molecule	ROS1+ NSCLC				
2	TQ-B3139	ALK/c-Met inhibitor	Small molecule	ALK+ NSCLC (1st line)				
3	Ryzneuta	LA G-CSF	Biologics	Neutropenia after chemotherapy				
4	TQB2450	Anti PD-L1	Biologics	SCLC, NSCLC, RCC, etc.				
5 ☆	TQB3616	CDK4/6 inhibitor	Small molecule	HR+, HER2- breast cancer				
6	FHND9041	3rd gen EGFR inhibitor	Small molecule	Tumor				
7	AL2846	Small molecule TKI	Small molecule	Neurofibroma, MPNST, NSCLC				
8	TQB3454	IDH1 inhibitor	Small molecule	Brain astrocytoma, BTC (IDH1 mutation)				
9 ☆	TQ-B3525	PI3K inhibitor	Small molecule	FL				
10	TQ05105	JAK2 inhibitor	Small molecule	GVHD, Myelofibrosis				
11	TQB3455	IDH2 inhibitor	Small molecule	Ovarian cancer (platinum-resistant), AML (IDH2 mutation)				
12	TQB3811	2nd gen TRK inhibitor	Small molecule	Solid tumor				
13 ☆	TQB2618	tim-3	Biologics	R/M NPC, SCLC				
14	TQB3728	IAP inhibitor	Small molecule	TNBC (postoperative adjuvant therapy)				
15	TQB2858	TGFβ bifunctional fusion proteins	Biologics	Pancreatic cancer, ASPS, Cervical cancer				
16	FS118	LAG-3/PD-L1 bispecific antibody	Biologics	Head and neck cancer, NSCLC, DLBCL				
17	TQB3602	Proteasome inhibitor	Small molecule	MM				
18 ☆	TQB3804	4th gen EGFR inhibitor	Small molecule	NSCLC				
19	TQ-B3234	MEK1/2 enzyme inhibitor	Small molecule	Neurofibroma, MPNST				
20	TQB3617	BET inhibitor	Small molecule	Tumor				
21	TQB3820	Targeting on E3-CRBN (new gen)	Small molecule	Liquid tumor, e.g. R/R MM, Lymphoma				
22	TQB3823	PARP inhibitor	Small molecule	CRPC				
23	TQB3824	CDC7 inhibitor	Small molecule	Tumor				
24	TQB3909	BCL-2 inhibitor	Small molecule	Tumor				
25	TQB3473	SYK inhibitor	Small molecule	CLL				
26	TQB3558	Trk inhibitor	Small molecule	Cancer pain				
27	TQB2868	PD1-TGFβ	Biologics	Tumor				
28 ☆	TQB2930	HER2/erbB2 protein	Biologics	Tumor				
29	TQB3915	SERCA	Small molecule	Tumor				
30	TQB2825	CD20/CD3 bispecific antibody	Biologics	CD20+ soft tumor				
31	TQB3720	AR antagonist	Small molecule	CRPC				
32 ☆	TQB2916	CD40 antibody	Biologics	Tumor				
33	TQB2928	CD47	Biologics	R/M solid tumor, R/R or initially diagnosed non-solid tumors that not suitable for current treatment				
34	FHND6091	UPP	Small molecule	Tumor				
35	FHND5071	TK	Small molecule	Tumor				
36	NTQ1062	Akt inhibitor	Small molecule	Solid tumor				
37	TQB2102	HER2 ADC	Biologics	HER2+ breast cancer, GC				
38	TQB2103	Claudin18.2 ADC	Biologics	Tumor				
39	TQB2934	BCMA/CD3 bispecific antibody	Biologics	R/R MM				
40	TQB3702	BTK inhibitor	Small molecule	R/R advanced hematological malignancies				
41	FS222	CD137/PD-L1 bispecific antibody	Biologics	Tumor				
42	FS120	OX40/CD137 bispecific antibody	Biologics	Tumor				
43	SB11285	STING agonist	Small molecule	Tumor				
44	BG136	Dectin-1, TLR4 (non-specific immune stimulators)	Biologics	Solid tumor				
45	TQB2223	LAG-3 antibody	Biologics	Tumor				
46	TCC1727	ATR inhibitor	Small molecule	Tumor				

Estimated peak sales over RMB 1bn ☆ Estimated peak sales between RMB 500mn and 1bn

Pipeline: Oncology
Generics and biosimilars: 16 products in clinical development

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

No.	Product/program	Indication	BE trial	I	Pivotal trial	ANDA/BLA
1 ☆	Rituximab	Malignant lymphoma, immune disease				
2 ☆	Trastuzumab	HER2 overexpression mBC				
3	Everolimus	RCC				
4	Palbociclib	Breast cancer				
5 ☆	rhFVIII	Hemorrhagic disease (hemophilia)				
6 ☆	Eltrombopag Olamine	ITP				
7	Bicalutamide	Prostate cancer				
8	Ruxolitinib	Myelofibrosis				
9	Nelarabine	Lymphocytic leukemia, Lymphoma				
10 ☆	Pertuzumab	mBC / neoadjuvant therapy for breast cancer				
11 ☆	rhFVIIa	Hemorrhagic disease				
12 ☆	Ramucirumab	GC				
13 ☆	Paclitaxel (albumin-bound)	Breast cancer				
14	Netupitant and Palonosetron Hydrochloride	CINV				
15	Degarelix Acetate	Prostate cancer				
16	Cabozantinib	RCC, Liver cancer				

☆ Estimated peak sales between RMB 500mn and 1bn

Pipeline: Liver disease

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Innovative:

No.	Program	Target / MOA	Type	Indication	I	II	III	NDA/BLA
1	Lanifibranor	Pan-PPAR	Small molecule	NASH				
2	TQ-A3334	TLR-7 agonist	Small molecule	CHB				
3	TQA3526	FXR agonist	Small molecule	NASH, PBC, etc				
4	TQA3810	Activating TLR-8 to enhance response of HBV-specific T cells, activating natural killer cells and MAIT cells to induce production of antiviral cytokines to inhibit HBV	Small molecule	HBV				
5	TQA2225	FGF21 fusion protein	Biologics	NASH				
6	TQA3729	Hepatitis B inhibitor JNJ-379	Small molecule	HBV				
7	TQA3605	HBV capsid inhibitor	Small molecule	CHB				
8	TQA2226	GLP-1 – FGF21-Fc fusion protein	Biologics	T2DM, NASH				

Generics and biosimilars:

No.	Product/program	Indication	BE trial	I	Pivotal trial	ANDA/BLA
1	Polyene Phosphatidylcholine	Liver nutrients, adjuvant liver disease therapy				
2	TAF	HBV				
3	Avatrombopag Tablets	Thrombocytopenia (liver disease)				
4	Indocyanine Green	Diagnosis of Cirrhosis, LF, Hepatitis, and Drug-induced hepatotoxicity				
5	Obeticholic Acid	PBC, NASH				

Estimated peak sales over RMB 1bn

Pipeline: Surgery/analgesic

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

Innovative:

No.	Program	Target / MOA	Type	Indication	I	II	III	NDA/BLA
1	PL-5	Antimicrobial peptide	Category I New Drug	Secondary wound infection				
2	RD81	Local anesthesia	Category II New Drug	DPNP (for external application)				
3	QJ-19	URAT1	Category I New Drug	Gout, Hyperuricemia	IND[1)]			
4	RD85	COX-2 inhibitor	Category II New Drug	ERAS	IND[1)]			

Generics and biosimilars:

No.	Product/program	Indication	BE trial	I	Pivotal trial	ANDA/BLA
1	Iguratimod Tablets	Arthrophlogosis				
2	Calcitriol	Osteoporosis				
3	Sugammadex Sodium Injection	Antagonize block produced by rocuronium or vecuronium				
4	Rocuronium Bromide Injection	Adjuvant to general anesthesia				
5	Frovatriptan	Migraine				
6	Cyclobenzaprine	Musculoskeletal pain				
7	Topiroxostat	Gout				
8	Flurbiprofen Transdermal Patches (imported)	Relieving pain from various conditions				
9	Pregabalin Sustained-release Tablets	DPN				
10	Loxoprofen Sodium	Relieving pain from various conditions				
11	Eldecalcitol	Osteoporosis				
12	Elagolix Sodium Tablets	Pain associated with endometriosis				

Note: 1) Anticipated to launch in around 3 years

Estimated peak sales over RMB 1bn

Pipeline: Respiratory
Innovative drugs: 10 products in clinical development

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

No.	Program	Target / MOA	Type	Indication	I	II	III	NDA/BLA
1	Ensitrelvir	3CL protease inhibitor	Small molecule	COVID-19				
2	☆ TQC3721	PDE3/4 dual inhibitors	Small molecule	COPD, Asthma				
3	☆ TQC2731	TSLP	Biologics	Asthma, Atopic dermatitis, Chronic sinusitis with nasal polyps				
4	TDI01	ROCK2 inhibitor	Small molecule	IPF, Pneumoconiosis, cGVHD, Covid-19				
5	TQC3564	CRTh2 antagonist	Small molecule	Asthma, Allergic rhinitis, Atopic rhinitis				
6	TQH2722	IL-4 antagonist	Biologics	Moderate to severe atopic dermatitis, chronic sinusitis with nasal polyps				
7	TQD3606	Inhibiting cell wall synthesis; β-Lactamase Inhibitors	Small molecule	CUTI				
8	TQC2938	ST2 antibody	Biologics	Asthma				
9	TCR1672	P2X3 inhibitor	Small molecule	Chronic cough and asthma, endometriosis, etc.				
10	TQD3524	Colistimethate Sodium	Small molecule	Effective against resistant G^- bacteria				

Estimated peak sales over RMB 1bn ☆ Estimated peak sales between RMB 500mn and 1bn

Pipeline: Respiratory
Generics and biosimilars: 18 products in clinical development

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

No.	Product/program	Indication	BE trial	I	Pivotal trial	ANDA/BLA
1	Oseltamivir Phosphate for Suspension	Flu				
2	Ornidazole Injection	Infections caused by susceptible protozoa and anaerobic bacteria				
3	Bromhexine Hydrochloride Injection	Chronic bronchitis and other respiratory diseases accompanied by phlegm, difficult to cough up				
4	Fudosteine oral solution	Expectorant: cough, chronic bronchitis, bronchiectasis, pneumoconiosis, emphysema, non-stereotypic acid-fast bacteria infected, etc.				
5	Tedizolid phosphate injection	Antibacterial				
6	Posaconazole Injection	Latest generation of triazole antifungal drug with widest antibacterial spectrum				
7	Letermovir Tablets	Cytomegalovirus infection				
8	Letermovir Injection	Cytomegalovirus infection				
9	Doripenem	Broad-spectrum antibiotic				
10	Arformoterol Tartrate	COPD				
11	Mepolizumab	Severe asthma				
12	Umeclidinium Bromide and Vilanterol Trifenatate	Maintenance treatment of airflow obstruction in COPD				
13	Fluticasone Furoate and Vilanterol Trifenatate	Asthma, COPD				
14	Indacaterol and Glycopyrrolate	COPD				
15	Amphotericin B Liposome for Injection	Patients with deep fungal infections; patients cannot use effective doses of amphotericin B due to renal injury or drug toxicity, or patients not responding to previous treatment with amphotericin B				
16	Beraprost Sodium sustained release tablet	Primary pulmonary hypertension and scleroderma complicated pulmonary hypertension				
17	Nintedanib	IPF				
18	Procaterol Hydrochloride Granules	Bronchodilator				

Disclaimer

中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED

This presentation has been prepared by Sino Biopharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) for reference purposes only. By reviewing or obtaining the information contained in this material, you hereby acknowledge and agree that the company, or any of its directors, shareholders, employees, agents, affiliates, consultants or representatives, makes no representations, warranties or undertakings, express or implied. And should not rely on the accuracy, fairness, completeness or correctness of the information or opinions provided or contained in this presentation. The company or any of its directors, shareholders, employees, agents, affiliates, consultants or representatives are not (by negligence or otherwise) caused by any information provided or contained in this presentation or other reasons related to this presentation. Any liability for any loss. Information provided or contained in this presentation is subject to change without notice and is not guaranteed.

This presentation does not constitute an offer to sell or issue, nor does it constitute an invitation or recommendation to purchase or subscribe for any securities sold by the Company. No part of this presentation constitutes a basis or reliance on any contract or investment decision relating to any securities or otherwise. This presentation does not contain all relevant information about the company or its securities, especially information relating to the risks and special considerations of investing in the company's securities. Nothing contained in this presentation shall be a commitment or representation of the company's past or future performance. Past performance is not guaranteed or predicts future performance. You acknowledge that any evaluations you may have about the Company will be independent of this presentation and that you will be solely responsible for your own assessment of the company's market and market position, and that you will conduct your own analysis and form your own responsibilities for the future performance of the company's business.

Certain statements in this presentation and other statements that the company may make are forward-looking statements. These statements reflect the company's intentions, beliefs or current expectations for the future. Such statements may be identified by the words "expect", "plan", "will", "estimate", "forecast", "intended", "expected", "believe", "confident" or similar Words. These forward-looking statements are not guarantees of future performance, but are based on assumptions about the company’s operations and other factors, many of which are beyond the company's control and, therefore, actual results may differ materially from these forward-looking statements. The company or any of its affiliates, consultants or representatives has no obligation or commitment to modify forward-looking statements to reflect future events or circumstances.

This presentation also includes adjusted financial indicators that are not intended to be considered as isolation or substitution of financial information prepared and stated in accordance with Hong Kong Financial Reporting Standards. In addition, the company's calculation of adjusted financial indicators may be different from the calculations used by other companies, so comparability may be limited.

The information contained in this document is highly confidential and is provided solely for the purpose of providing you with information and for your use only in connection with the use of this presentation. The information contained in this document may not be reproduced, reproduced, redistributed or disclosed to any other person in whole or in part. This presentation may not be forwarded, distributed or reproduced in whole or in part.

Your viewing, access or participation in this presentation is the basis for your knowledge and confidentiality of the contents of this presentation and these materials. You agree not to remove these materials or any materials provided in connection with the conference room in which the document is provided. You further agree that you may not photograph, reproduce or otherwise reproduce this presentation or transfer it to any other person for any purpose during this briefing or in a conference room. At the end of this presentation, you must return this presentation and all other materials provided in connection with the company. Your access to, access to, or participation in this presentation is hereby agreed to be bound by the above limitations.